滤泡性淋巴瘤-话题@MedSci

#滤泡性淋巴瘤#

69篇内容 | 3918人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1278825, encodeId=f0b312e882513, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, objectType=article, longId=727501, objectId=ccafe275011b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ccafe275011b, replyNumber=0, likeNumber=111, createdTime=2022-05-23, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ccafe275011b, moduleTitle=HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ccafe275011b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278824, encodeId=811412e882440, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Nat Med：Tisagenlecleucel治疗复发性或难治性滤泡性淋巴瘤效果如何？, objectType=article, longId=292206, objectId=f8ff29220653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8ff29220653, replyNumber=0, likeNumber=124, createdTime=2021-12-20, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8ff29220653, moduleTitle=Nat Med：Tisagenlecleucel治疗复发性或难治性滤泡性淋巴瘤效果如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8ff29220653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278823, encodeId=e0aa12e88231e, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=BJH：局限性滤泡性淋巴瘤放疗后影像监测的影响, objectType=article, longId=220120, objectId=cf7122012077, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf7122012077, replyNumber=0, likeNumber=102, createdTime=2021-11-12, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf7122012077, moduleTitle=BJH：局限性滤泡性淋巴瘤放疗后影像监测的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cf7122012077)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278822, encodeId=9ff312e8822bb, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Eur J Cancer：原发难治性滤泡性淋巴瘤的不良预后和高组织转化率, objectType=article, longId=217117, objectId=ae8721e117eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae8721e117eb, replyNumber=0, likeNumber=97, createdTime=2021-09-16, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae8721e117eb, moduleTitle=Eur J Cancer：原发难治性滤泡性淋巴瘤的不良预后和高组织转化率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae8721e117eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278821, encodeId=6e8912e8821a3, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood Cancer J：奥比妥珠单抗+阿特珠单抗+来那度胺可有效治疗复发/难治性滤泡性淋巴瘤！, objectType=article, longId=216221, objectId=210121622181, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=210121622181, replyNumber=0, likeNumber=96, createdTime=2021-08-25, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=210121622181, moduleTitle=Blood Cancer J：奥比妥珠单抗+阿特珠单抗+来那度胺可有效治疗复发/难治性滤泡性淋巴瘤！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=210121622181)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278820, encodeId=403212e882078, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Clin Cancer Res：滤泡性淋巴瘤患者接受alloSCT或autoSCT后随访9年的结果, objectType=article, longId=215851, objectId=541c21585197, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=541c21585197, replyNumber=0, likeNumber=95, createdTime=2021-08-18, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=541c21585197, moduleTitle=Clin Cancer Res：滤泡性淋巴瘤患者接受alloSCT或autoSCT后随访9年的结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=541c21585197)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278819, encodeId=72b812e88196e, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=滤泡性淋巴瘤一线治疗新基石，可及性备受关注, objectType=article, longId=210365, objectId=1c4221036554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c4221036554, replyNumber=0, likeNumber=63, createdTime=2021-04-25, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c4221036554, moduleTitle=滤泡性淋巴瘤一线治疗新基石，可及性备受关注, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c4221036554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278818, encodeId=051712e881881, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, objectType=article, longId=209158, objectId=40ec209158b9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=40ec209158b9, replyNumber=0, likeNumber=87, createdTime=2021-03-31, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=40ec209158b9, moduleTitle=日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=40ec209158b9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278817, encodeId=f16612e881740, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood Advances：老年滤泡性淋巴瘤患者不该因年龄太大而丧失治疗资格, objectType=article, longId=209018, objectId=9317209018c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9317209018c7, replyNumber=0, likeNumber=87, createdTime=2021-03-27, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9317209018c7, moduleTitle=Blood Advances：老年滤泡性淋巴瘤患者不该因年龄太大而丧失治疗资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9317209018c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278816, encodeId=cdbd12e88165a, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, objectType=article, longId=206517, objectId=375420651efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=375420651efe, replyNumber=0, likeNumber=81, createdTime=2021-02-02, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=375420651efe, moduleTitle=美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=375420651efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278815, encodeId=848c12e88156f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！, objectType=article, longId=201959, objectId=fc0c201959b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc0c201959b7, replyNumber=0, likeNumber=101, createdTime=2020-10-12, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc0c201959b7, moduleTitle=Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc0c201959b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278814, encodeId=ff6112e8814fa, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Blood：维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤, objectType=article, longId=199989, objectId=134a199989af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=134a199989af, replyNumber=0, likeNumber=82, createdTime=2020-08-29, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=134a199989af, moduleTitle=Blood：维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=134a199989af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278813, encodeId=c92812e881389, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点, objectType=article, longId=198822, objectId=494f19882295, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=494f19882295, replyNumber=0, likeNumber=76, createdTime=2020-08-07, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=494f19882295, moduleTitle=诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=494f19882295)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278812, encodeId=e56712e881236, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, objectType=article, longId=197588, objectId=c63a19e588ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c63a19e588ba, replyNumber=0, likeNumber=69, createdTime=2020-07-17, rootId=0, userName=仁心济世, userId=fa4716, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c63a19e588ba, moduleTitle=罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c63a19e588ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278811, encodeId=91a412e8811ac, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=Hematol Oncol：雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达, objectType=article, longId=196148, objectId=6a1f19614846, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a1f19614846, replyNumber=0, likeNumber=101, createdTime=2020-06-21, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a1f19614846, moduleTitle=Hematol Oncol：雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a1f19614846)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278810, encodeId=ce8512e88103a, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, objectType=article, longId=194365, objectId=0d90194365fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d90194365fe, replyNumber=0, likeNumber=81, createdTime=2020-05-20, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d90194365fe, moduleTitle=滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0d90194365fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278809, encodeId=107612e88091f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, objectType=article, longId=193348, objectId=1c5c193348ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c5c193348ad, replyNumber=0, likeNumber=80, createdTime=2020-05-03, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c5c193348ad, moduleTitle=AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c5c193348ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278808, encodeId=7df712e88083f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=FDA授予Kymriah治疗滤泡性淋巴瘤再生医学高级疗法（RMAT）认定, objectType=article, longId=192833, objectId=390d19283388, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=390d19283388, replyNumber=0, likeNumber=92, createdTime=2020-04-25, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=390d19283388, moduleTitle=FDA授予Kymriah治疗滤泡性淋巴瘤再生医学高级疗法（RMAT）认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=390d19283388)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278807, encodeId=094112e88079f, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=FDA授予Umbralisib孤儿药认定，以治疗滤泡性淋巴瘤（FL）, objectType=article, longId=189499, objectId=623b18949984, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=623b18949984, replyNumber=0, likeNumber=66, createdTime=2020-03-08, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=623b18949984, moduleTitle=FDA授予Umbralisib孤儿药认定，以治疗滤泡性淋巴瘤（FL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=623b18949984)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278806, encodeId=58bb12e8806fb, content=<a href='/topic/show?id=5bd36658e94' target=_blank style='color:#2F92EE;'>#滤泡性淋巴瘤#</a>, objectTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, objectType=article, longId=189157, objectId=3e3b18915ec7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e3b18915ec7, replyNumber=0, likeNumber=70, createdTime=2020-03-04, rootId=0, userName=gongliu, userId=1a5a149, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e3b18915ec7, moduleTitle=英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3e3b18915ec7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

滤泡性淋巴瘤

2020-05-29

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

HAEMATOLOGICA：PET-CT状态对接受自体干细胞移植的复发性滤泡性淋巴瘤患者无进展生存期的影响

2022-05-23

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Nat Med：Tisagenlecleucel治疗复发性或难治性滤泡性淋巴瘤效果如何？

2021-12-20

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

BJH：局限性滤泡性淋巴瘤放疗后影像监测的影响

2021-11-12

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Eur J Cancer：原发难治性滤泡性淋巴瘤的不良预后和高组织转化率

2021-09-16

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood Cancer J：奥比妥珠单抗+阿特珠单抗+来那度胺可有效治疗复发/难治性滤泡性淋巴瘤！

2021-08-25

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Clin Cancer Res：滤泡性淋巴瘤患者接受alloSCT或autoSCT后随访9年的结果

2021-08-18

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

滤泡性淋巴瘤一线治疗新基石，可及性备受关注

2021-04-25

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

日本厚生劳动省批准CAR-T细胞疗法Breyanzi治疗DLBCL和滤泡性淋巴瘤

2021-03-31

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood Advances：老年滤泡性淋巴瘤患者不该因年龄太大而丧失治疗资格

2021-03-27

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

美国FDA授予Bcl-2抑制剂APG-2575第五个孤儿药称号，用以治疗滤泡性淋巴瘤（FL）

2021-02-02

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Lancet oncol：EZH2抑制剂，有望成为滤泡性淋巴瘤患者的新选择！

2020-10-12

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Blood：维奈托克联合利妥昔单抗±苯达莫司汀治疗复发性/难治性滤泡性淋巴瘤

2020-08-29

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

诺华CAR-T疗法Kymriah：达到滤泡性淋巴瘤试验终点

2020-08-07

仁心济世 (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

罗氏CD20xCD3双特异性抗体Mosunetuzumab治疗滤泡性淋巴瘤，获得FDA的突破性治疗指定

2020-07-17

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

Hematol Oncol：雌激素受体-α在1-2级和3级滤泡性淋巴瘤患者滤泡树状细胞上的差异性表达

2020-06-21

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

滤泡性淋巴瘤一线治疗将有新标准！新一代抗CD20单抗佳罗华®中国获批

2020-05-20

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

AACR 2020：伊布替尼+利妥昔单抗治疗滤泡性淋巴瘤III期研究启动（PERSPECTIVE研究）

2020-05-03

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

FDA授予Kymriah治疗滤泡性淋巴瘤再生医学高级疗法（RMAT）认定

2020-04-25

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

FDA授予Umbralisib孤儿药认定，以治疗滤泡性淋巴瘤（FL）

2020-03-08

gongliu (审核中...)

前往app查看评论内容

#滤泡性淋巴瘤#

英国NICE推荐将来那度胺与利妥昔单抗联合用于治疗滤泡性淋巴瘤

2020-03-04

科室
- - 订阅+
  - 更多科室
工具
服务